
DBD Stock Forecast & Price Target
DBD Analyst Ratings
Bulls say
Diebold Nixdorf Inc has demonstrated a strong performance in its Retail segment, with revenues of $255 million reflecting an 8.1% increase quarter-over-quarter and a 7.8% rise year-over-year, while gross margins improved by 100 basis points to 24.7%. The company is on track to achieve significant growth in free cash flow, with projections estimating nearly double the figure for 2025 compared to 2024, indicating sustainable financial health. Additionally, robust year-over-year earnings per share growth is anticipated for 2026, supported by revenue growth and targeted margin expansions, which underscores a positive outlook for the company’s financial performance.
Bears say
Diebold Nixdorf's stock faces a negative outlook primarily due to technological missteps and an inability to innovate, which could hinder its revenue growth and profitability, particularly within its Banking segment where gross margins have recently declined. The company anticipates significant operational expense savings but may struggle to offset tariff-related costs and faces growing pricing pressure from increased competition, further complicating its financial stability. Additionally, factors such as supply chain disruptions, lower than expected demand for upgrades, and foreign exchange volatility pose substantial risks that could exacerbate the company’s challenges moving forward.
This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.
DBD Analyst Forecast & Price Prediction
Start investing in DBD
Order type
Buy in
Order amount
Est. shares
0 shares